Merus N.V (MRUS)

Etorro trading 970x250
Merus N.V (MRUS) Logo

About Merus N.V

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Address: Yalelaan 62, Utrecht, Netherlands, 3584 CM

Merus N.V News and around…

Latest news about Merus N.V (MRUS) common stock and company :

Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)
10 Nov, 2021 Yahoo! Finance

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual). The prerecorded fireside chat will be available starting on Thursday, November 18, 2021 at 8:00 am

Investors Grab MRUS Even Cheaper Than Its Secondary Stock Offering
08 Nov, 2021 FinancialContent

Looking back to 3 days ago, Merus NV (MRUS) priced a 3,859,650 share secondary stock offering at $28.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

Could The Merus N.V. (NASDAQ:MRUS) Ownership Structure Tell Us Something Useful?
08 Nov, 2021 Yahoo! Finance

If you want to know who really controls Merus N.V. ( NASDAQ:MRUS ), then you'll have to look at the makeup of its share...

The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
05 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug ...

Merus Announces Pricing of Public Offering of Common Shares
05 Nov, 2021 Yahoo! Finance

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public offering of 3,859,650 common shares, at a public offering price of $28.50 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up

Merus N.V. Announces Proposed Public Offering of Common Shares
04 Nov, 2021 Yahoo! Finance

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of its common shares (the “Offer Shares”). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates
02 Nov, 2021 Yahoo! Finance

Merus N.V. (MRUS) delivered earnings and revenue surprises of 40.91% and 29.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update
02 Nov, 2021 Yahoo! Finance

Merus participated in a Type B meeting with the FDA regarding its zenocutuzumab development program and obtained alignment with FDA on registration approach for a potential tumor agnostic indicationMerus presented early clinical data on MCLA-158 at the AACR-NCI-EORTC Virtual International Conference reporting interim data for patients with advanced head and neck squamous cell carcinoma (HNSCC) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MR

Will Merus N.V. (MRUS) Report Negative Q3 Earnings? What You Should Know
28 Oct, 2021 Yahoo! Finance

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Where Do Hedge Funds Stand On Merus N.V. (MRUS)?
26 Oct, 2021 Yahoo! Finance

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 873 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of June 30th, 2021. […]

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Notable Merus Insider Makes $31M Sale
11 Oct, 2021 FinancialContent

Mark Lampert, 10% Owner at Merus (NASDAQ:MRUS), made a large insider sell on October 8, according to a new SEC filing. What Happened: ...

45 Biggest Movers From Yesterday
08 Oct, 2021 FinancialContent

Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. ...

Strength Seen in Merus N.V. (MRUS): Can Its 37.5% Jump Turn into More Strength?
08 Oct, 2021 Yahoo! Finance

Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Merus Clears Key Benchmark, Hitting 90-Plus RS Rating
08 Oct, 2021 FinancialContent

Merus shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher
07 Oct, 2021 FinancialContent

Toward the end of trading Thursday, the Dow traded up 1.29% to 34,860.01 while the NASDAQ rose 1.47% to 14,714.54. The S&P also ...

4 Biotech To Watch As Pfizer Seeks FDA Approval For Child Vaccines
07 Oct, 2021 FinancialContent
Merus Stock Flirts With Breakout After Experimental Drug Shrinks All Tumors
07 Oct, 2021 FinancialContent

Merus stock popped Thursday after the biotech's experimental drug shrank tumors in every head-and-neck cancer patient in an early-stage test.

Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide
07 Oct, 2021 FinancialContent

Midway through trading Thursday, the Dow traded up 1.51% to 34,938.25 while the NASDAQ rose 1.64% to 14,739.43. The S&P also rose, ...

28 Stocks Moving In Thursday's Mid-Day Session
07 Oct, 2021 Yahoo! Finance

Gainers Camber Energy, Inc.. (NYSE: CEI) jumped 44.2% to $1.3102 after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial statements of Viking. Paltalk, Inc. (NASDAQ: PALT) shares jumped 40.1% to $9.71 after dropping over 15% on Wednesday. Paltalk’s recent filing showed registration for $50 million mixed securities shelf offering. Merus N.V. (NASDAQ: MRUS) surged 38.7% to $27.74 as the company presented early clinical data on MCLA-158 and preclinical data on zenocutu

Here's Why Merus Stock Is Flying Higher Today
07 Oct, 2021 FinancialContent

This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results.

Why Are Merus Shares Soaring Thursday?
07 Oct, 2021 FinancialContent

Merus N.V.(NASDAQ: MRUS) haspresented data on MCLA-158 and preclinical data on zenocutuzumab(Zeno) at the ...

Mid-Morning Market Update: Markets Open Higher; Conagra Brands Profit Beats Views
07 Oct, 2021 FinancialContent

Following the market opening Thursday, the Dow traded up 1.51% to 34,936.37 while the NASDAQ rose 1.56% to 14,728.21. The S&P also ...

Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
07 Oct, 2021 Yahoo! Finance

Tumor shrinkage and partial responses observed in patients with advanced head and neck squamous cell carcinoma (HNSCC) treated with MCLA-158In preclinical studies, Zeno observed to block cell growth 100 fold more potently than anti-HER3 antibody alone UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Bicl

Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
30 Sep, 2021 FinancialContent
Those who invested in Merus (NASDAQ:MRUS) five years ago are up 173%
07 Sep, 2021 Yahoo! Finance

When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...

Merus to Participate in Upcoming Investor Conferences
07 Sep, 2021 FinancialContent
58 Biggest Movers From Yesterday
20 Aug, 2021 FinancialContent

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares climbed 63.7% to close at $1.22 on Thursday after dropping 12% ...

Analysts Expect SMMV To Hit $42
12 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $42.34 per unit.

Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates
06 Aug, 2021 Yahoo! Finance

Merus N.V. (MRUS) delivered earnings and revenue surprises of -18.33% and 58.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Merus N.V (MRUS) is a NASDAQ Common Stock listed in , ,

970x250